MX2021013814A - Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida. - Google Patents

Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.

Info

Publication number
MX2021013814A
MX2021013814A MX2021013814A MX2021013814A MX2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A MX 2021013814 A MX2021013814 A MX 2021013814A
Authority
MX
Mexico
Prior art keywords
fluorocyclopropyl
oxadiazol
pyridine
imidazo
carboxamide
Prior art date
Application number
MX2021013814A
Other languages
English (en)
Inventor
Xiaoyang Wang
Andreas Kordikowski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021013814A publication Critical patent/MX2021013814A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona formas cristalinas de N-(5-(5-((1R,2S)-2-fluorociclopropil)-1,2,4- oxadiazol-3-il)-2-met ilfenil)imidazo[1,2-a]piridin-3-carboxamida, en particular la Variante A y un cocristal de ácido fumárico de N-(5-(5-((1R,2S)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-met ilfenil)imidazo[1,2- a]piridin-3-carboxamida. La presente invención también se refiere a los procesos para la preparación de dichas formas cristalinas. Más aún, la invención se refiere a una composición farmacéutica que comprende dicha Variante A de N-(5-(5-((1R,2S)-2-fluorociclopropil)-1,2,4-oxadiazol-3-il)-2-met ilfenil)imidazo[1,2- a]piridin-3-carboxamida o dicho cocristal del ácido fumárico de N-(5-(5-((1R,2S)-2-fluorociclopropil)-1,2,4- oxadiazol-3-il)-2-metilfenil)imidazo[1,2-a]piridin-3-carboxamida y al menos un excipiente farmacéuticamente aceptable. La composición farmacéutica de la presente invención se puede utilizar a manera de un medicamento, en particular para el tratamiento y/o profilaxis contra una enfermedad asociada a mastocitos, una enfermedad respiratoria, un trastorno inflamatorio, síndrome del intestino irritable (IBS), enfermedad inflamatoria intestinal (IBD), un trastorno autoinmunitario, una enfermedad metabólica, una enfermedad por fibrosis, una enfermedad cutánea, hipertensión arterial pulmonar (PAH) e hipertensión pulmonar primaria (PPH).
MX2021013814A 2019-05-13 2020-05-13 Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida. MX2021013814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019086582 2019-05-13
PCT/CN2020/090060 WO2020228746A1 (en) 2019-05-13 2020-05-13 Crystalline forms of n- (5- (5- ( (1r, 2s) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide

Publications (1)

Publication Number Publication Date
MX2021013814A true MX2021013814A (es) 2022-02-10

Family

ID=73289607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013814A MX2021013814A (es) 2019-05-13 2020-05-13 Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.

Country Status (14)

Country Link
US (1) US20220194936A1 (es)
EP (1) EP3969453A4 (es)
JP (1) JP2022533340A (es)
KR (1) KR20220007650A (es)
CN (1) CN114096538A (es)
AU (1) AU2020274564A1 (es)
BR (1) BR112021022685A2 (es)
CA (1) CA3139552A1 (es)
IL (1) IL287877A (es)
MA (1) MA55976A (es)
MX (1) MX2021013814A (es)
SG (1) SG11202112281UA (es)
TW (1) TW202108581A (es)
WO (1) WO2020228746A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11767319B2 (en) 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
TW202237096A (zh) * 2020-11-19 2022-10-01 瑞士商諾華公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法
TW202237097A (zh) * 2020-11-19 2022-10-01 美商第三諧波生物公司 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012302176A1 (en) * 2011-09-01 2014-04-17 Irm Llc Compounds and compositions as c-kit kinase inhibitors
JP2014525450A (ja) * 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー ｃ−Ｋｉｔキナーゼ阻害剤としての化合物および組成物
ES2761332T3 (es) * 2011-09-01 2020-05-19 Novartis Ag Compuestos y composiciones como inhibidores de la cinasa c-kit
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Also Published As

Publication number Publication date
IL287877A (en) 2022-01-01
KR20220007650A (ko) 2022-01-18
CA3139552A1 (en) 2020-11-19
JP2022533340A (ja) 2022-07-22
EP3969453A1 (en) 2022-03-23
BR112021022685A2 (pt) 2022-03-29
WO2020228746A1 (en) 2020-11-19
AU2020274564A1 (en) 2021-12-09
SG11202112281UA (en) 2021-12-30
CN114096538A (zh) 2022-02-25
MA55976A (fr) 2022-03-23
US20220194936A1 (en) 2022-06-23
EP3969453A4 (en) 2023-01-18
TW202108581A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
MX2021013814A (es) Formas cristalinas de n-(5-(5-((1r,2s)-2-fluorociclopropil)-1,2,4- oxadiazol-3-yl)-2- metilfenil)imidazo[1,2-a]piridin-3-carboxamida.
WO2009033711A3 (en) Use of glp-1 as a therapeutic agent
WO2009033783A3 (en) Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
WO2009043505A3 (en) Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer
WO2009033805A3 (en) Use of somatostatin-14 as a therapeutic agent
WO2009040068A3 (en) Use of a peptide as a therapeutic agent
WO2009033668A3 (en) Use of a peptide as a therapeutic agent
WO2009033755A3 (en) Use of l-carnosine as a therapeutic agent
WO2009033681A3 (en) Cyclo-argd as a therapeutic agent
WO2009046845A3 (en) Use of a lactoferrin partial peptide peptide as a therapeutic agent
WO2009033712A3 (en) Use of melanotan ii as a therapeutic agent
WO2009039991A3 (en) Use of aviptadil as a therapeutic agent
WO2009033778A3 (en) Mage-3 antigen and others for use as a therapeutic agent
WO2009040072A3 (en) Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis
WO2009046864A3 (en) Use of the human pancreatic polypeptide as a therapeutic agent
WO2009033660A3 (en) Use of octreotide as a therapeutic agent
WO2009033779A3 (en) Nociceptin for use as a therapeutic agent